Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin Therapy
NCT03959501
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Type 2 Diabetes
Ketonemia
Interventions
DRUG:
Dapagliflozin 10 mg
DRUG:
Sitagliptin 100mg
Sponsor
The University of Hong Kong